Blood levels of donor-specific human leukocyte antigen antibodies after renal transplantation: Resolution of rejection in the presence of circulating donor-specific antibody

Transplantation

Volumn 84, Issue 7, 2007, Pages 876-884

  Higgins, Rob ^a,d   Hathaway, Mark ^b   Lowe, David ^b   Lam, For ^a   Kashi, Habib ^a   Tan, Lam Chin ^a   Imray, Chris ^a   Fletcher, Simon ^a   Zehnder, Daniel ^a,c   Chen, Klaus ^a   Krishnan, Nithya ^a   Hamer, Rizwan ^a,c   Briggs, David ^b  

^a UNIVERSITY HOSPITALS COVENTRY AND WARWICKSHIRE NHS TRUST   (United Kingdom)

^b NHS BLOOD AND TRANSPLANT   (United Kingdom)

^c UNIVERSITY OF WARWICK   (United Kingdom)

^d UNIVERSITY HOSPITAL COVENTRY   (United Kingdom)

Author keywords

Accommodation; Antibody incompatible transplantation; HLA antibodies; Plasmapheresis

Indexed keywords

HLA ANTIBODY; LEUKOCYTE ANTIBODY; LEUKOCYTE ANTIGEN; ANTIBODY; HLA ANTIGEN; IMMUNOSUPPRESSIVE AGENT; POLYSTYRENE DERIVATIVE;

ADULT; ANTIBODY SPECIFICITY; ARTICLE; BLOOD LEVEL; CLINICAL ARTICLE; COMPLEMENT DEPENDENT CYTOTOXICITY; FLOW CYTOMETRY; FLUORESCENCE; GRAFT REJECTION; HUMAN; KIDNEY TRANSPLANTATION; LIVING DONOR; PLASMAPHERESIS; PRIORITY JOURNAL; STATISTICAL ANALYSIS; AGED; BIOPSY; CHEMISTRY; GRAFT SURVIVAL; HISTOCOMPATIBILITY TEST; IMMUNOLOGY; METHODOLOGY; MIDDLE AGED; TIME;

ADULT; AGED; ANTIBODIES; BIOPSY; FLOW CYTOMETRY; GRAFT SURVIVAL; HISTOCOMPATIBILITY TESTING; HLA ANTIGENS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; LIVING DONORS; MIDDLE AGED; PLASMAPHERESIS; POLYSTYRENES; TIME FACTORS;

EID: 38449105912     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.tp.0000284729.39137.6e     Document Type: Article

References (31)

1. Williams GM, Hume DM, Hudson RP Jr, Morris PJ, Kano K, Milgrom F. "Hyperacute" renal-homograft rejection in man. N Engl J Med 1968; 279: 611.
2. Morris PJ, Williams GM, Hume DM, Mickey MR, Terasaki PI. Serotyping for homotransplantations XII. Ocurrence of cytotoxic antibodies following kidney transplantation in man. Transplantation 1968; 6: 392.
3. Taube DH, Williams DG, Cameron JS, et al. Renal transplantation after removal and prevention of resynthesis of HLA antibodies. Lancet 1984; 1: 824.
4. Palmer A, Taube D, Welsh K, Bewick M, Gjorstrup P, Thick M. Removal of anti-HLA antibodies by extracorporeal immunoadsorption to enable renal transplantation. Lancet 1989; 1: 10.
5. Higgins RM, Bevan DJ, Carey BS, et al. Prevention of hyperacute rejection by removal of antibodies to HLA immediately before renal transplantation. Lancet 1996; 348: 1208.
6. Montgomery RA, Zachary AA, Racusen LC, et al. Plasmapheresis and intravenous immune globulin provides effective rescue therapy for refractory humoral rejection and allows kidneys to be successfully transplanted into cross-match-positive recipients. Transplantation 2000; 70: 887.
7. Gloor JM, DeGoey SR, Pineda AA, et al. Overcoming a positive cross-match in living-donor kidney transplantation. Am J Transplant 2003; 3: 1017.
8. Zachary AA, Montgomery RA, Ratner LE, et al. Specific and durable elimination of antibody to donor HLA antigens in renal-transplant patients. Transplantation 2003; 76: 1519.
9. Gloor JM, DeGoey S, Ploeger N, et al. Persistence of low levels of alloantibody after desensitization in crossmatch-positive living-donor kidney transplantation. Transplantation 2004; 78: 221.
10. Haas M, Rahman MH, Racusen LC, et al. C4d and C3d staining in biopsies of ABO- and HLA-incompatible renal allografts:correlation with histologic findings. Am J Transplant 2006; 6: 1829.
11. Haas M, Montgomery RA, Segev DL, et al. Subclinical acute antibody-mediated rejection in positive crossmatch renal allografts. Am J Transplant 2007; 7: 576.
12. Gloor JM, Cosio FG, Rea DJ, et al. Histologic findings one year after positive crossmatch or ABO blood group incompatible living donor kidney transplantation. Am J Transplant 2006; 6: 1841.
13. Takahashi K, Saito K, Takahara S, et al. Excellent long-term outcome of ABO-incompatible living donor kidney transplantation in Japan. Am J Transplant 2004; 4: 1089.
14. Ishida H, Miyamoto N, Shirakawa H, et al. Evaluation of immunosuppressive regimens in ABO-Incompatible living kidney transplantation-single center analysis. Am J Transplant 2007; 7: 825.
15. Aikawa A, Yamashita M, Hadano T, et al. ABO incompatible kidney transplantation - immunological aspect. Exp Clin Transplant 200; 1: 112.
16. King KE, Warren DS, Samaniego-Picota Mm, Campbell-Lee, Montgomery RA, Baldwin WM. Antibody, complement and accommodation in ABO-incompatible transplants. Curr Opin Immunol 2004; 16: 545.
17. Bevan DJ, Carey BS, Vaughan RW, et al. Modulation of anti-HLA antibody production following renal transplantation in sensitised, immunoadsorbed patients. Transplant Proc 1997; 29: 1448.
18. Pei R, Lee JH, Shih NJ, Chen M, Terasaki PI. Single human leucocyte antigen flow cytometry beads for accurate identification of human leucocyte antigen antibody specificities. Transplantation 2003; 75: 43.
19. Pei R, Lee J, Chen T, Rojo S, Terasaki PI. Flow cytometric detection of HLA antibodies using a spectrum of microbeads. Hum Immunol 1999; 60: 1293.
20. Sumitran-Karuppan S. The clinical importance of choosing the right assay for detection of HLA-specific donor-reactive antibodies. Transplantation 1999; 68: 502.
21. Montgomery RA, Zachary AA. Transplanting patients with a positive donor-specific crossmatch:Asingle centre's perspective. Pediatr Transplantation 2004; 8: 535.
22. Koo DD, Roberts IS, Quiroga I, et al. C4d deposition in early renal allograft protocol biopsies. Transplantation 2004; 78: 398.
23. Magil AB, Tinckam KJ. Focal peritubular capillary C4d deposition in acute rejection. Neprol Dial Transplant 2006; 21: 1382.
24. Bohmig GA, Exner M, Habicht A, et al. Capillary C4d deposition in kidney allografts. A specific marker of alloantibody-dependent graft injury. J Am Soc Nephrol 2002; 134: 1091.
25. Racusen LC, Colvin RB, Solez K, et al. Antibody-mediated rejection criteria - an addition to the Banff 97 classification of renal allograft rejection. Am J Transplant 2003; 3: 708.
26. Locke JE, Zachary AA, Haas M, et al. The utility of splenectomy as rescue treatment for severe acute antibody mediated rejection. Am J Transplant 2007; 7: 842.
27. Zachary AA, Montgomery RA, Leffell MS. Factors associated with and predictive of persistence of donor-specific antibody after treatment with plasmapheresis and intravenous immunoglobulin. Human Immunol 2005; 66: 364.
28. Stegall MD, Gloor J, Winters JL, Moore SB, DeGoey S. A comparison of plasmapheresis versus high-dose IVIG desensitisation in renal allograft recipients with high levels of donor specific alloantibody. Am J Transplant 2006; 6: 346.
29. Sis B, Kaplan B, Halloran PF. Histologic findings from positive cross-match or ABO-incompatible renal allografts; accommodation or chronic allograft injury? Am J Transplant 2006; 6: 1753.
30. Williams JM, Holzknecht ZE, Plummer TB, Lin SS, Brunn GJ, Platt JL. Acute vascular rejection and accommodation: Divergent outcomes of the humoral response to organ transplantation. Transplantation 2004; 78: 1471.
31. Salama AD, Delikouras A, Pusey CD, et al. Transplant accommodation in highly sensitized patients: A potential role for Bcl-xL and alloantibody. Am J Transplant 2001; 1: 260.